$BBLG News

Bone Biologics Files Prospectus To Offer Up To 6.46M Shares Of Common Stock By Selling Stockholders

BBLG Secures Financing for Critical Trials

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1

Bone Biologics Announces Validated Shelf Life Extension Of Its rhNELL-1 Protein Product To 29 Months

BBLG In Good Shape as Critical Tests Underway

Bone Biologics Q1 EPS $(0.43) Beats $(0.54) Estimate

Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.20/Share Price Valuation

BBLG Financials Show Company in Solid Shape

BBLG Approaching Crucial Stage

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Bone Biologics Extends Shelf Life Of rhNELL‑1 To 24 Months, Meeting Forecasts

Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.25 Price Valuation

BBLG Has Cash for Approval Push

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Bone Biologics shares are trading higher after the company's CEO issued a stockholder letter highlighting NB1 clinical progress.